Inflammatory biomarkers in Alzheimer's disease plasma

Annex: NIMA–Wellcome Trust Consortium for Neuroimmunology of Mood Disorders and Alzheimer's Disease, NIMA Consortium

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Introduction: Plasma biomarkers for Alzheimer's disease (AD)diagnosis/stratification are a “Holy Grail” of AD research and intensively sought; however, there are no well-established plasma markers. Methods: A hypothesis-led plasma biomarker search was conducted in the context of international multicenter studies. The discovery phase measured 53 inflammatory proteins in elderly control (CTL; 259), mild cognitive impairment (MCI; 199), and AD (262)subjects from AddNeuroMed. Results: Ten analytes showed significant intergroup differences. Logistic regression identified five (FB, FH, sCR1, MCP-1, eotaxin-1)that, age/APOε4 adjusted, optimally differentiated AD and CTL (AUC: 0.79), and three (sCR1, MCP-1, eotaxin-1)that optimally differentiated AD and MCI (AUC: 0.74). These models replicated in an independent cohort (EMIF; AUC 0.81 and 0.67). Two analytes (FB, FH)plus age predicted MCI progression to AD (AUC: 0.71). Discussion: Plasma markers of inflammation and complement dysregulation support diagnosis and outcome prediction in AD and MCI. Further replication is needed before clinical translation.
Original languageEnglish
JournalAlzheimer's and Dementia
DOIs
Publication statusPublished - 2019

Cite this

Annex: NIMA–Wellcome Trust Consortium for Neuroimmunology of Mood Disorders and Alzheimer's Disease, & NIMA Consortium (2019). Inflammatory biomarkers in Alzheimer's disease plasma. Alzheimer's and Dementia. https://doi.org/10.1016/j.jalz.2019.03.007
Annex: NIMA–Wellcome Trust Consortium for Neuroimmunology of Mood Disorders and Alzheimer's Disease ; NIMA Consortium. / Inflammatory biomarkers in Alzheimer's disease plasma. In: Alzheimer's and Dementia. 2019.
@article{52b60963ae6a4d4c8d3d2c92b9d4a260,
title = "Inflammatory biomarkers in Alzheimer's disease plasma",
abstract = "Introduction: Plasma biomarkers for Alzheimer's disease (AD)diagnosis/stratification are a “Holy Grail” of AD research and intensively sought; however, there are no well-established plasma markers. Methods: A hypothesis-led plasma biomarker search was conducted in the context of international multicenter studies. The discovery phase measured 53 inflammatory proteins in elderly control (CTL; 259), mild cognitive impairment (MCI; 199), and AD (262)subjects from AddNeuroMed. Results: Ten analytes showed significant intergroup differences. Logistic regression identified five (FB, FH, sCR1, MCP-1, eotaxin-1)that, age/APOε4 adjusted, optimally differentiated AD and CTL (AUC: 0.79), and three (sCR1, MCP-1, eotaxin-1)that optimally differentiated AD and MCI (AUC: 0.74). These models replicated in an independent cohort (EMIF; AUC 0.81 and 0.67). Two analytes (FB, FH)plus age predicted MCI progression to AD (AUC: 0.71). Discussion: Plasma markers of inflammation and complement dysregulation support diagnosis and outcome prediction in AD and MCI. Further replication is needed before clinical translation.",
author = "{Annex: NIMA–Wellcome Trust Consortium for Neuroimmunology of Mood Disorders and Alzheimer's Disease} and {NIMA Consortium} and Morgan, {Angharad R.} and Samuel Touchard and Claire Leckey and Caroline O'Hagan and Nevado-Holgado, {Alejo J.} and Frederik Barkhof and Lars Bertram and Olivier Blin and Isabelle Bos and Valerija Dobricic and Sebastiaan Engelborghs and Giovanni Frisoni and Lutz Fr{\"o}lich and Silvey Gabel and Peter Johannsen and Petronella Kettunen and Iwona Kłoszewska and Cristina Legido-Quigley and Alberto Lle{\'o} and Pablo Martinez-Lage and Patrizia Mecocci and Karen Meersmans and Molinuevo, {Jos{\'e} Luis} and Gwendoline Peyratout and Julius Popp and Jill Richardson and Isabel Sala and Philip Scheltens and Johannes Streffer and Hikka Soininen and Mikel Tainta-Cuezva and Charlotte Teunissen and Magda Tsolaki and Rik Vandenberghe and Visser, {Pieter Jelle} and Stephanie Vos and Lars-Olof Wahlund and Anders Wallin and Sarah Westwood and Henrik Zetterberg and Simon Lovestone and Morgan, {B. Paul} and Bullmore, {Edward T.} and Junaid Bhatti and Chamberlain, {Samuel J.} and Correia, {Marta M.} and Crofts, {Anna L.} and Amber Dickinson and Foster, {Andrew C.} and Kitzbichler, {Manfred G.}",
year = "2019",
doi = "10.1016/j.jalz.2019.03.007",
language = "English",
journal = "Alzheimers & Dementia",
issn = "1552-5260",
publisher = "Elsevier",

}

Annex: NIMA–Wellcome Trust Consortium for Neuroimmunology of Mood Disorders and Alzheimer's Disease & NIMA Consortium 2019, 'Inflammatory biomarkers in Alzheimer's disease plasma' Alzheimer's and Dementia. https://doi.org/10.1016/j.jalz.2019.03.007

Inflammatory biomarkers in Alzheimer's disease plasma. / Annex: NIMA–Wellcome Trust Consortium for Neuroimmunology of Mood Disorders and Alzheimer's Disease; NIMA Consortium.

In: Alzheimer's and Dementia, 2019.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Inflammatory biomarkers in Alzheimer's disease plasma

AU - Annex: NIMA–Wellcome Trust Consortium for Neuroimmunology of Mood Disorders and Alzheimer's Disease

AU - NIMA Consortium

AU - Morgan, Angharad R.

AU - Touchard, Samuel

AU - Leckey, Claire

AU - O'Hagan, Caroline

AU - Nevado-Holgado, Alejo J.

AU - Barkhof, Frederik

AU - Bertram, Lars

AU - Blin, Olivier

AU - Bos, Isabelle

AU - Dobricic, Valerija

AU - Engelborghs, Sebastiaan

AU - Frisoni, Giovanni

AU - Frölich, Lutz

AU - Gabel, Silvey

AU - Johannsen, Peter

AU - Kettunen, Petronella

AU - Kłoszewska, Iwona

AU - Legido-Quigley, Cristina

AU - Lleó, Alberto

AU - Martinez-Lage, Pablo

AU - Mecocci, Patrizia

AU - Meersmans, Karen

AU - Molinuevo, José Luis

AU - Peyratout, Gwendoline

AU - Popp, Julius

AU - Richardson, Jill

AU - Sala, Isabel

AU - Scheltens, Philip

AU - Streffer, Johannes

AU - Soininen, Hikka

AU - Tainta-Cuezva, Mikel

AU - Teunissen, Charlotte

AU - Tsolaki, Magda

AU - Vandenberghe, Rik

AU - Visser, Pieter Jelle

AU - Vos, Stephanie

AU - Wahlund, Lars-Olof

AU - Wallin, Anders

AU - Westwood, Sarah

AU - Zetterberg, Henrik

AU - Lovestone, Simon

AU - Morgan, B. Paul

AU - Bullmore, Edward T.

AU - Bhatti, Junaid

AU - Chamberlain, Samuel J.

AU - Correia, Marta M.

AU - Crofts, Anna L.

AU - Dickinson, Amber

AU - Foster, Andrew C.

AU - Kitzbichler, Manfred G.

PY - 2019

Y1 - 2019

N2 - Introduction: Plasma biomarkers for Alzheimer's disease (AD)diagnosis/stratification are a “Holy Grail” of AD research and intensively sought; however, there are no well-established plasma markers. Methods: A hypothesis-led plasma biomarker search was conducted in the context of international multicenter studies. The discovery phase measured 53 inflammatory proteins in elderly control (CTL; 259), mild cognitive impairment (MCI; 199), and AD (262)subjects from AddNeuroMed. Results: Ten analytes showed significant intergroup differences. Logistic regression identified five (FB, FH, sCR1, MCP-1, eotaxin-1)that, age/APOε4 adjusted, optimally differentiated AD and CTL (AUC: 0.79), and three (sCR1, MCP-1, eotaxin-1)that optimally differentiated AD and MCI (AUC: 0.74). These models replicated in an independent cohort (EMIF; AUC 0.81 and 0.67). Two analytes (FB, FH)plus age predicted MCI progression to AD (AUC: 0.71). Discussion: Plasma markers of inflammation and complement dysregulation support diagnosis and outcome prediction in AD and MCI. Further replication is needed before clinical translation.

AB - Introduction: Plasma biomarkers for Alzheimer's disease (AD)diagnosis/stratification are a “Holy Grail” of AD research and intensively sought; however, there are no well-established plasma markers. Methods: A hypothesis-led plasma biomarker search was conducted in the context of international multicenter studies. The discovery phase measured 53 inflammatory proteins in elderly control (CTL; 259), mild cognitive impairment (MCI; 199), and AD (262)subjects from AddNeuroMed. Results: Ten analytes showed significant intergroup differences. Logistic regression identified five (FB, FH, sCR1, MCP-1, eotaxin-1)that, age/APOε4 adjusted, optimally differentiated AD and CTL (AUC: 0.79), and three (sCR1, MCP-1, eotaxin-1)that optimally differentiated AD and MCI (AUC: 0.74). These models replicated in an independent cohort (EMIF; AUC 0.81 and 0.67). Two analytes (FB, FH)plus age predicted MCI progression to AD (AUC: 0.71). Discussion: Plasma markers of inflammation and complement dysregulation support diagnosis and outcome prediction in AD and MCI. Further replication is needed before clinical translation.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85064805360&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/31047856

U2 - 10.1016/j.jalz.2019.03.007

DO - 10.1016/j.jalz.2019.03.007

M3 - Article

JO - Alzheimers & Dementia

JF - Alzheimers & Dementia

SN - 1552-5260

ER -

Annex: NIMA–Wellcome Trust Consortium for Neuroimmunology of Mood Disorders and Alzheimer's Disease, NIMA Consortium. Inflammatory biomarkers in Alzheimer's disease plasma. Alzheimer's and Dementia. 2019. https://doi.org/10.1016/j.jalz.2019.03.007